Advanced Viral Research Corp. Hires Public Relations Firm.YONKERS, N.Y. -- Advanced Viral Research Corporation (OTCBB OTCBB See OTC Bulletin Board (OTCBB). : ADVR ADVR Association of Directors of Volunteer Resources (Canada) ), a research based biopharmaceutical company dedicated to anti-cancer drug discovery and development, announced today it has appointed the life sciences marketing communications firm The Signature Agency to assist in its overall branding and investor communications. Advanced Viral Research Corporation is developing a new class of cytoprotective drug which may be useful in the treatment of cachexia cachexia /ca·chex·ia/ (kah-kek´se-ah) a profound and marked state of constitutional disorder; general ill health and malnutrition. (body wasting), appetite loss, and lethargy in patients with cancer and HIV-AIDS. The compound also is being evaluated in a Phase II topical wound healing wound healing Physiology The repair of a wound Steps Inflammation, repair and closure, remodeling, final healing; repair of incisions may be either simple–'clean' wounds with little loss of tissue heal by 'primary intention', or 'dirty' wounds heal by study after demonstrating accelerated wound healing properties in a well established animal model at the University of Miami This article is about the university in Coral Gables, Florida. For the university in Oxford, Ohio, see Miami University. The University of Miami (also known as Miami of Florida,[2] UM,[3] or just The U . The Signature Agency, a full-service North Carolina North Carolina, state in the SE United States. It is bordered by the Atlantic Ocean (E), South Carolina and Georgia (S), Tennessee (W), and Virginia (N). Facts and Figures Area, 52,586 sq mi (136,198 sq km). Pop. based public relations agency, provides a wide range of services that include corporate communications, investor relations, web-site design and product marketing strategies. "The Signature Agency will assist us in providing superior service to our stakeholders by keeping them better informed of the issues and events that impact our growth," said Stephen M. Elliston, President and Chief Executive Officer. Advanced Viral Research Corp. is a New York based biopharmaceutical company dedicated to improving patients' lives by researching, developing and bringing to market new and effective therapies for the control of symptoms associated with cancer and other serious diseases. Its initial compound AVR (Automatic Voltage Regulation) See voltage regulator. 118 represents a new class of cytoprotective agent that targets among other things, cachexia related disorders. AVR118 has also shown to have topical wound healing properties in animal models. Various degenerative conditions associated with body wasting (cachexia) such as cancer, HIV-AIDS and chronic inflammation are potential disease targets for AVR118 therapy. Note: This news release contains forward-looking statements that involve risks associated with clinical development, regulatory approvals, including application to the FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. , product commercialization and other risks described from time to time in the SEC reports filed by the Company. AVR118 is not approved by the U.S. Food and Drug Administration or any comparable agencies of any other countries. There is no assurance that the Company will be able to secure the financing necessary to continue and/or complete the clinical trials of AVR118 or satisfy certain other conditions relating to clinical trials including obtaining adequate insurance on terms acceptable to the Company. The Company undertakes no obligation to update or revise the information contained in this announcement whether as a result of new information, future events or circumstances or otherwise. For further information regarding Advanced Viral Research Corp., please visit our website at http://www.adviral.com. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion